Abstract
Background and Aim The impact of health reforms such as affordability care act (ACA) and Medicaid extension program on health insurance coverage among acute pancreatitis (AP) patients in the United States (US) is unknown. We report the trends and forecasts for the uninsured rates among acute pancreatitis (AP) patients in the US.
Methods We included non-elderly adult patients (aged 18 -64 years), hospitalized with AP in the nationwide inpatient sample database years 2004-2019. We calculated the percentage of uninsured and Medicaid patients for each year and applied joinpoint (JP) regression model to study the trends.
Results The uninsured rates among patients hospitalized with AP were almost twice compared to the national average rates for all hospitalized patients. Uninsured rates were higher among Hispanic and African American races, rural location, lower income quartiles and in the southern US regions. A statistically significant decline was observed during 2013-2016 with an APC of - 12.23 (−20- -4); p<0.01). The decline was apparent among all racial groups, locations and income groups but not in the southern region where gap in the uninsured rates worsened compared to other geographical regions. The trends reversed more recently, and the uninsured rates surged in 2018 for the first time after 2010. In 2019, 12.5% AP patients were uninsured compared to 11.6% in 2017.
Conclusions The ACA and Medicaid extension programs had a positive impact on the health insurance coverage among patients hospitalized with AP including racial minorities and low-income groups. However, the positive impact of ACA on the uninsured rates has decreased in most recent years (2017-2019) and may disappear completely in the coming years.
Competing Interest Statement
Kumar, Vivek: None Barkoudah, Ebrahim: Dr. Barkoudah reports research support payments from the National Institutes of Health/National Heart, Lung, and Blood Institute, Bristol Myers Squibb and Janssen, payments made to Brigham and Women's Hospital for performing clinical endpoints sponsored by various entities and Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer and Portola, and travel expenses from Alexion. Jin, David X: None Banks, Peter: None McNabb-Baltar, Julia: None
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study utilizes data from the Nationwide Inpatient Sample database (NIS) which is publicly available and can be obtained from, Purchase HCUP Data. Healthcare Cost and Utilization Project (HCUP). May 2022. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/tech_assist/centdist.jsp.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Disclosures:
Guarantor of the article: Kumar, Vivek & McNabb-Baltar, Julia
Financial support: None
Potential competing interests Kumar, Vivek: None
Barkoudah, Ebrahim: Dr. Barkoudah reports research support payments from National Institutes of Health/National Heart, Lung, and Blood Institute, Bristol Myers Squibb and Janssen, payments made to Brigham and Women’s Hospital for performing clinical endpoints sponsored by various entities and Advisory Board fees from Bristol Myers Squibb, Janssen, Novartis, Pfizer and Portola, and travel expenses from Alexion.
Jin, David X: None
Banks, Peter: None
McNabb-Baltar, Julia: None
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.